Illumina Reports 4 Percent Revenue Decline for Q4; Rejects Roche Offer Again | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its fourth-quarter revenues dropped 4 percent year over year, while issuing a separate statement once again rejecting Roche's offer to acquire the company for $44.50 per share, or $5.7 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.